The pathogenetic mechanisms underlying the onset of adrenocortical tumors (ACTs) are still largely unknown. Recently, more attention has been paid to the role of insulin and insulin-like growth factor (IGF) system on general tumor development and progression. Increased levels of insulin, IGF-1 and IGF-2 are associated with tumor cell growth and increased risk of cancer promotion and progression in patients with type 2 diabetes. Insulin resistance and compensatory hyperinsulinemia may play a role in adrenal tumor growth through the activation of insulin and IGF-1 receptors. Interestingly, apparently non-functioning ACTs are often associated with a high prevalence of insulin resistance and metabolic syndrome. However, it is unclear if ACT develops from a primary insulin resistance and compensatory hyperinsulinemia or if insulin resistance is only secondary to the slight cortisol hypersecretion by ACT. The aim of this review is to summarize the current evidence regarding the relationship between hyperinsulinemia and adrenocortical tumors.

Altieri, B., Tirabassi, G., Della Casa, S., Ronchi, C. L., Balercia, G., Orio, F., Pontecorvi, A., Colao, A., Muscogiuri, G., Adrenocortical tumors and insulin resistance: What is the first step?, <<INTERNATIONAL JOURNAL OF CANCER>>, 2016; 138 (12): 2785-2794. [doi:10.1002/ijc.29950] [http://hdl.handle.net/10807/91868]

Adrenocortical tumors and insulin resistance: What is the first step?

Altieri, Barbara
Primo
;
Della Casa, Silvia;Pontecorvi, Alfredo;Muscogiuri, Giovanna
2016

Abstract

The pathogenetic mechanisms underlying the onset of adrenocortical tumors (ACTs) are still largely unknown. Recently, more attention has been paid to the role of insulin and insulin-like growth factor (IGF) system on general tumor development and progression. Increased levels of insulin, IGF-1 and IGF-2 are associated with tumor cell growth and increased risk of cancer promotion and progression in patients with type 2 diabetes. Insulin resistance and compensatory hyperinsulinemia may play a role in adrenal tumor growth through the activation of insulin and IGF-1 receptors. Interestingly, apparently non-functioning ACTs are often associated with a high prevalence of insulin resistance and metabolic syndrome. However, it is unclear if ACT develops from a primary insulin resistance and compensatory hyperinsulinemia or if insulin resistance is only secondary to the slight cortisol hypersecretion by ACT. The aim of this review is to summarize the current evidence regarding the relationship between hyperinsulinemia and adrenocortical tumors.
2016
Inglese
Altieri, B., Tirabassi, G., Della Casa, S., Ronchi, C. L., Balercia, G., Orio, F., Pontecorvi, A., Colao, A., Muscogiuri, G., Adrenocortical tumors and insulin resistance: What is the first step?, <<INTERNATIONAL JOURNAL OF CANCER>>, 2016; 138 (12): 2785-2794. [doi:10.1002/ijc.29950] [http://hdl.handle.net/10807/91868]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/91868
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 26
social impact